Boyd Relac joins the Pharmagen Executive Team as Chief Operating Officer ("COO")

SILVER SPRING, Md., April 29, 2014 /PRNewswire/ -- Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen") today announced that Boyd Relac has been appointed as its Chief Operating Officer ("COO"). Boyd brings with him over 20 years of experience including holding notable senior level positions with such companies as Dentsply International, Patterson Companies, Maly's Midwest and most recently L'Oreal/SalonCentric. Boyd also formed and honed his leadership skills as a U.S. Army Officer in elite airborne and special operations units. Boyd was awarded the Bronze Star Medal for meritorious service during Operation Desert Storm and earned 3 Meritorious Service Medals for leadership in command and staff positions of special operations units.

"I have known and worked with Boyd over the past 10 years," says Richard Wolpow, Pharmagen's Chairman and previous Interim-COO. "There was a short list of candidates to take over the COO role, and Boyd was on the top of that list. Boyd has the perfect mix of that entrepreneurial spirit, large corporate experience and military commitment to excellence. Boyd will be an integral part to the success of the Company's long term consolidation plan that has been in the works since this past October. I am proud to have him as part of the Pharmagen Team," Wolpow concluded.

From 1997 to 2008, Mr. Relac held various positions of increasing responsibility in the dental industry at Dentsply International and Patterson Dental. He built a reputation for impactful revenue growth as a result of his ability to execute on the detailed strategic sales and marketing plans he wrote for both companies. In 2008 he transitioned to the professional beauty industry as a VP/GM initially executing a turn-around and quick sale of a privately held $90MM distributor to L'Oreal. At L'Oreal he again lead above-budgeted growth progressing from Regional Vice President leading sales execution and integrating acquisitions in the Midwest, to the national sales leadership role where he initially served as Vice President, Sales and Strategic Development evolving to focus his energies on integrating nine acquisitions plus restructuring sales teams.

"When I first spoke with Richard about the Company and its consolidation plan I immediately appreciated the role and responsibility that Pharmagen has in contributing to the safety and efficacy of sterile and non-sterile compounded pharmaceuticals in the U.S. today, not to overshadow the void Pharmagen fills in finding and sourcing scarce pharmaceuticals for hospitals every day. As I began to understand the vision for Pharmagen and met the dedicated professionals on the team, I quickly realized the opportunity as COO was a perfect fit for my experience and desire to serve a company and its emerging customer base. I am already proud to be associated with a company such as Pharmagen because of the commitment we have to the highest quality that cGMP compliance brings to the forefront. It's already a rewarding experience and we are just getting started!" stated Mr. Relac.

About Pharmagen

Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. offers innovative solutions to the nations sterile pharmaceutical crisis. With a multi-solution approach, Pharmagen is helping to meet the demand of the health provider market through independent wholesale, compounding, and IT solutions. Nationally focused, Pharmagen is a distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find.

Contact: 888-264-4597 or [email protected]
Follow Us on Twitter: @pharmagenrx or
The Drug Shortage Report http://drugshortagereport.blogspot.com/

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pharmagen disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Pharmagen, Inc.